Journal of Chest Surgery

  • 제57권4호
  • /
  • Pages.351-359
  • /
  • 2024
  • /
  • 2765-1606(pISSN)
  • /
  • 2765-1614(eISSN)
대한심장혈관흉부외과학회 (The Korean Society for Thoracic and Cardiovascular Surgery)
권호 표지
DOI QR코드

DOI QR Code

Risk Factor Analysis of Morbidity and 90-Day Mortality of Curative Resection in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer after Induction Concurrent Chemoradiation Therapy

  • Ga Hee Jeong (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Junghee Lee (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yeong Jeong Jeon (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Seong Yong Park (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Hong Kwan Kim (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yong Soo Choi (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jhingook Kim (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Young Mog Shim (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jong Ho Cho (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2023.11.27
  • 심사 : 2024.01.26
  • 발행 : 2024.07.05
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Major pulmonary resection after neoadjuvant concurrent chemoradiation therapy (nCCRT) is associated with a substantial risk of postoperative complications. This study investigated postoperative complications and associated risk factors to facilitate the selection of suitable surgical candidates following nCCRT in stage IIIA-N2 non-small cell lung cancer (NSCLC). Methods: We conducted a retrospective analysis of patients diagnosed with clinical stage IIIA-N2 NSCLC who underwent surgical resection following nCCRT between 1997 and 2013. Perioperative characteristics and clinical factors associated with morbidity and mortality were analyzed using univariable and multivariable logistic regression. Results: A total of 574 patients underwent major lung resection after induction CCRT. Thirty-day and 90-day postoperative mortality occurred in 8 patients (1.4%) and 41 patients (7.1%), respectively. Acute respiratory distress syndrome (n=6, 4.5%) was the primary cause of in-hospital mortality. Morbidity occurred in 199 patients (34.7%). Multivariable analysis identified significant predictors of morbidity, including patient age exceeding 70 years (odds ratio [OR], 1.8; p=0.04), low body mass index (OR, 2.6; p=0.02), and pneumonectomy (OR, 1.8; p=0.03). Patient age over 70 years (OR, 1.8; p=0.02) and pneumonectomy (OR, 3.26; p<0.01) were independent predictors of mortality in the multivariable analysis. Conclusion: In conclusion, the surgical outcomes following nCCRT are less favorable for individuals aged over 70 years or those undergoing pneumonectomy. Special attention is warranted for these patients due to their heightened risks of respiratory complications. In high-risk patients, such as elderly patients with decreased lung function, alternative treatment options like definitive CCRT should be considered instead of surgical resection.

키워드

참고문헌

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. https://doi.org/10.3322/caac.21166 
  2. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8. https://doi.org/10.1056/NEJM199401203300301 
  3. Ahn YC, Park K, Kim DY, et al. Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer. Acta Oncol 2001;40:588-92. https://doi.org/10.1080/028418601750444123 
  4. Kang MK, Ahn YC, Lim DH, et al. Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer. J Korean Med Sci 2006;21:229-35. https://doi.org/10.3346/jkms.2006.21.2.229 
  5. Kim KJ, Ahn YC, Lim DH, et al. Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. Lung Cancer 2007;55:329-36. https://doi.org/10.1016/j.lungcan.2006.10.024 
  6. Lee H, Ahn YC, Pyo H, et al. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. Ann Surg Oncol 2014;21:2083-90. https://doi.org/10.1245/s10434-014-3540-x 
  7. Doddoli C, Thomas P, Thirion X, Seree Y, Giudicelli R, Fuentes P. Postoperative complications in relation with induction therapy for lung cancer. Eur J Cardiothorac Surg 2001;20:385-90. https://doi.org/10.1016/s1010-7940(01)00764-3 
  8. Roberts JR, Eustis C, Devore R, Carbone D, Choy H, Johnson D. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 2001;72:885-8. https://doi.org/10.1016/s0003-4975(01)02836-3 
  9. Patel RL, Townsend ER, Fountain SW. Elective pneumonectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1992;54:84-8. https://doi.org/10.1016/0003-4975(92)91145-y 
  10. Wada H, Nakamura T, Nakamoto K, Maeda M, Watanabe Y. Thirty-day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg 1998;115:70-3. https://doi.org/10.1016/s0022-5223(98)70444-1 
  11. Duque JL, Ramos G, Castrodeza J, et al. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogenico de la Sociedad Espanola de Neumologia y Cirugia Toracica. Ann Thorac Surg 1997;63:944-50. https://doi.org/10.1016/s0003-4975(97)00051-9 
  12. Birim O, Kappetein AP, Bogers AJ. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg 2005;28:759-62. https://doi.org/10.1016/j.ejcts.2005.06.046 
  13. Balducci L. ESH-SIOG International Conference on Haematological Malignancies in the Elderly. Expert Rev Hematol 2010;3:675-7. https://doi.org/10.1586/ehm.10.72 
  14. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-31. https://doi.org/10.1200/JCO.2007.10.6559 
  15. Extermann M. Integrating a geriatric evaluation in the clinical setting. Semin Radiat Oncol 2012;22:272-6. https://doi.org/10.1016/j.semradonc.2012.05.003 
  16. Wedding U, Kodding D, Pientka L, Steinmetz HT, Schmitz S. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007;64:1-9. https://doi.org/10.1016/j.critrevonc.2007.05.001 
  17. Puts MT, Hardt J, Monette J, Girre V, Springall E, Alibhai SM. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 2012;104:1133-63. https://doi.org/10.1093/jnci/djs285 
  18. Licker M, Spiliopoulos A, Frey JG, et al. Risk factors for early mortality and major complications following pneumonectomy for nonsmall cell carcinoma of the lung. Chest 2002;121:1890-7. https://doi.org/10.1378/chest.121.6.1890 
  19. Van Raemdonck DE, Schneider A, Ginsberg RJ. Surgical treatment for higher stage non-small cell lung cancer. Ann Thorac Surg 1992;54:999-1013. https://doi.org/10.1016/0003-4975(92)90677-v 
  20. Mansour Z, Kochetkova EA, Santelmo N, et al. Risk factors for early mortality and morbidity after pneumonectomy: a reappraisal. Ann Thorac Surg 2009;88:1737-43. https://doi.org/10.1016/j.athoracsur.2009.07.016 
  21. Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992;101:1332-7. https://doi.org/10.1378/chest.101.5.1332 
  22. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86. https://doi.org/10.1016/S0140-6736(09)60737-6 
  23. Bagan P, Berna P, De Dominicis F, et al. Nutritional status and postoperative outcome after pneumonectomy for lung cancer. Ann Thorac Surg 2013;95:392-6. https://doi.org/10.1016/j.athoracsur.2012.06.023 
  24. Thomas PA, Berbis J, Falcoz PE, et al. National perioperative outcomes of pulmonary lobectomy for cancer: the influence of nutritional status. Eur J Cardiothorac Surg 2014;45:652-9. https://doi.org/10.1093/ejcts/ezt452 
  25. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92. https://doi.org/10.1200/JCO.1995.13.8.1880 
  26. Deslauriers J, Ginsberg RJ, Piantadosi S, Fournier B. Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer. Chest 1994;106(6 Suppl):329S-330S. https://doi.org/10.1378/chest.106.6_supplement.329s